Biopsy Devices Market Size, Share & Analysis Report By Product (Needle Based Biopsy Instruments, Procedure Trays, Localization Wires, Liquid Biopsy Instruments and Others), By Application (Breast Biopsy, Gastroenterology Biopsy, Prostate Biopsy, Liver Biopsy), By End Users (Hospitals and Breast Care Centres, Diagnostic & Imaging Centres, Research and Academic Institutes and Other End Users) and Regional Forecasts, 2024 – 2032

Biopsy Devices Market is estimated to be worth USD 3.59 Billion in 2024 and is projected to grow at a CAGR of 10% between 2024 to 2032. The study has considered the base year as 2023, which estimates the market size of the market, and the forecast period is 2024 to 2032.

The report analyses and forecasts the market size, in terms of value (USD Billion), for the market. The report segments the market and forecasts it by Product, by Application, by End User, and by region/country.

Biopsy devices are medical instruments used to extract tissue samples from the body for further examination. These examinations are crucial in diagnosing various medical conditions, most importantly cancer. There's a wide range of biopsy devices available, each designed for a specific purpose and tissue type. Such as needle biopsy devices which are thin, hollow needles which are used to collect tissue samples. Surgical biopsy devices which are used for more invasive procedures to collect the larger tissue samples.

The type of biopsy device used will depend on the specific location and type of tissue being sampled, as well as the doctor's preference. Biopsy procedures are constantly evolving, with new technologies emerging to improve accuracy, minimize patient discomfort, and allow for faster sample collection and analysis.

Region wise Comparison:

After reviewing the data shown below, it can be determined that the North America region dominates the Biopsy Devices Market for the following reasons.
The North American region is significantly dominating the Biopsy Devices Market. Due to the increasing prevalence of the cancer cases within the region and well-established healthcare infrastructure with advanced medical facilities. For instances, according to the article published in the ACS journals, it was forecasted that in the United States, projections indicate that 1,958,310 new cancer cases and 609,820 cancer deaths will occur in 2023.

Segmentations

By Product

• Needle Based Biopsy Instruments
• Procedure Trays
• Localization Wires
• Liquid Biopsy Instruments
• Others

By Application

• Breast Biopsy
• Gastroenterology Biopsy
• Prostate Biopsy
• Liver Biopsy

By End Users

• Hospitals and Breast Care Centres
• Diagnostic & Imaging Centres
• Research and Academic Institutes
• Other End Users

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East and Africa

By Product

Based on Product, the Biopsy Devices Market is bifurcated into Needle Based Biopsy instruments, Procedure Trays, Localization Wires, Liquid Biopsy Instruments and Others– where Needle Based Biopsy instruments segment is dominating and ahead in terms of share.

By End Users

Based on End Users, the Biopsy Devices Market is bifurcated into Hospitals and Breast Care Centres, Diagnostic & Imaging Centres, Research and Academic Institutes and Other End Users– where Hospitals and Breast Care Centres segment is dominating and ahead in terms of share.

Key Players

• Boston Scientific Corporation
• Intact Medical Corporation
• Gallini Medical
• TSK Laboratory Europe BV
• Argon Medical Devices

DRIVERS

Increasing Cancer Prevalence

The increasing prevalence of the cancer cases worldwide and growing healthcare facilities infrastructure in developing countries had significantly played an important role as the market growth driver for the Biopsy Devices Market. For instance, according to the data published by world health organization, globally, cancer is a major health concern, ranking as the second leading cause of death. In 2018, an estimated 9.6 million people died from cancer, representing roughly one in six deaths. When broken down by gender, common cancers differ. Men are more likely to experience lung, prostate, colorectal, stomach, and liver cancers, while women are more susceptible to breast, colorectal, lung, cervical, and thyroid cancers.

OPPORTUNITY

Innovations

Liquid biopsy is a groundbreaking diagnostic technique offering a minimally invasive way to analyse cancer. It uses body fluids like blood, saliva, and urine to gather information on the molecular makeup of tumours. This powerful tool plays a vital role in personalized medicine by enabling real-time monitoring of disease progression. Liquid biopsies analyse components like circulating tumour cells (CTCs), cell-free tumour DNA (ctDNA), circulating microRNAs (ctmiRNAs), and extracellular vehicles. This analysis has significantly improved cancer management by facilitating early detection, prognosis, and tailored treatment plans. Currently, liquid biopsy is integrated into numerous clinical trials which had opened the market growth opportunity for the Biopsy Devices.